For the three months ended March 31, 2024, from continuing operations: Revenues of $662.1 millionGAAP net loss of $81.6 millionAdjusted EBITDA of $29.5 millionGAAP and adjusted diluted earnings (loss) per share of $(0.91) and $(0.04), respectivelyBook-to-bill ratio of 1.11x, resulting in >1.2x book-to-bill for the trailing nine monthsPlanned divestiture of assets relating to the Endpoint Clinical and Patient Access businesses on track DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the ...